Olema Oncology price target raised to $36 from $28 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Olema Oncology (OLMA) to $36 from $28 and keeps a Buy rating on the shares. The firm views Roche’s positive giredestrant results as “clearly indicative of the benefit” of oral selective estrogen receptor degraders. The adjuvant setting now could be another expansion indication for Olema’s palazestrant, which creates “significant upside market opportunity as a setting where patients are on therapy for up to 10 years,” the analyst tells investors in a research note.